Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab can prolong remissions, conference told

Infliximab can prolong remissions in some of the most severe cases of Crohn's disease, researchers have reported.

News image

fiogf49gjkf04

A multi-center research team conducted the first large-scale trial of infliximab - also known as 'Remicade' - as maintenance therapy.

After 30 weeks of the study, patients receiving infusions of infliximab every 8 weeks were twice as likely to be in remission as those who were not receiving the drug.

The results of the trial, known as ACCENT-I, were revealed at the Digestive Disease Week meeting in Atlanta, United States.

Infliximab was approved by the Food and Drug Administration 3 years ago for short-term treatment of moderate to severe Crohn's disease and is the only non-steroidal medication indicated for the treatment of fistulas.

The study's director, Dr Stephen Hanauer, a Professor of Medicine at the University of Chicago, said it was the first therapy that truly allowed the disease to be managed over time.

"Ongoing treatment with infliximab decreased disease activity, prevented sudden attacks, and enabled patients to reduce - or, in many cases, completely eliminate - steroids," he commented.

Proportion of patients in remission at Week 30:
Placebo group: 21%
Infliximab, Group II: 39%
Infliximab, Group III: 45%
Digestive Disease Week

Almost 600 patients with moderate to severe Crohn's disease were involved in the study at 55 centers in North America, Europe, and Israel.

All patients received an initial dose of infliximab. The 335 patients (59%) who responded to the initial dose were randomized to one of 3 treatment groups.

All three groups received infusions at Weeks 2, 6, 14, 22, and 30 of the study. Group I received placebo (an infusion containing no medication), Group II received 5 mg/kg of infliximab, and Group III received 5 mg/kg of infliximab at Weeks 2 and 6, followed by 10 mg/kg at Weeks 14, 22, and 30.

By Week 30, patients in Groups II and III were twice as likely to be in remission as patients in Group I who received only the placebo.

Dr Hanauer said that almost 21% of the patients who received placebo had no symptoms at 30 weeks, but nearly 39% of those on the lower dose of infliximab, and 45% of those on the higher dose, were in complete remission.

He said infliximab also helped patients reduce their reliance on steroids; and patients reported higher quality-of-life scores at Week 30 than patients receiving the placebo.

"It would make a real difference for patients if we had alternatives to steroids, or better ways to reduce the steroid dose," said Hanauer.

However, infliximab has also been found to increase the risk of serious infection because it suppresses part of the immune response.

There are also reports of serious infusion reactions with hives, difficulty breathing, and low blood pressure, and in rare cases, people with de-myelinating disease who were treated with infliximab have seen their symptoms intensify.

Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com

Digestive Disease Week
23 May 2001

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us